Current trends in the pharmacological treatment of alcohol-related problems

References

• Research advances in new psychopharmacological treatments for alcoholism, CA Naranjo, EM Sellers. Elsevier, Amsterdam 1985
   Google Scholar
• Naranjo CA, Cappell H, Sellers EM. Pharmacological control of alcohol consumption: Tactics for the identification and testing of new drugs. Addict Behav 1981; 6: 261–269
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Sullivan JT, Lawrin MO, Sellers EM. Strategies for the identification and testing of new pharmacological modulators of ethanol consumption. Brain reward systems and abuse, J Engel, L Oreland, DH Ingvar, B Pernow, S Rossner, LA Pellborn. Raven Press, New York 1987; 129–145, In
   Google Scholar
• Sellers EM, Naranjo CA, Peachey JE. Drugs to decrease alcohol consumption. New Engl J Med 1981; 305: 1255–1262
   PubMed Web of Science ®Google Scholar
• Edwards G. Drug treatments for drinking problems: Finding a way forward. Pharmacological treatments for alcoholism, G Edwards, J Littleton. Methuen, New York 1984; 3–11, In
   Google Scholar
• Naranjo CA. Drug treatments for alcoholism: The need for innovation. Research advances in new psychopharmacological treatments for alcoholism, CA Naranjo, EM Sellers. Elsevier, Amsterdam 1985; 1–9, In
   Google Scholar
• Naranjo CA, Sellers EM. Clinical trials for testing new drugs to decrease alcohol consumption. Proceedings of the 10th International Congress of Pharmacology. Elsevier, Amsterdam 1987, In (in press)
   Google Scholar
• Council of Scientific Affairs of the AMA (Chicago). Alcohol and the driver. JAMA 1986; 255: 522–527
   PubMed Web of Science ®Google Scholar
• Naranjo CA. Recent advances in the pharmacotherapy of alcoholism. Clinical pharmacology and therapeutics, M Velasco. Excerpta Medica, Amsterdam 1983; 132–139, In
   Google Scholar
• Suzdak PD, Glowa JR, Crawley JN, Schwartz RD, Skolnick P, Paul SM. A selective imidazobenzodiazepine antagonist of ethanol in the rat. Science 1986; 234: 1243–1247
   PubMed Web of Science ®Google Scholar
• Lister RG, Nutt DJ. Is Ro15-4513 a specific alcohol antagonist?. Trends Neurosci 1987; 10: 223–225
   Web of Science ®Google Scholar
• Sellers EM, Naranjo CA. Strategies for improving the treatment of alcohol withdrawal. Research advances in new psychopharmacological treatments for alcoholism, CA Naranjo, EM Sellers. Elsevier, Amsterdam 1985; 157–168, In
   Google Scholar
• Naranjo CA, Sellers EM. Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome. Recent developments in alcoholism, M Galanter. Plenum, New York 1986; 4: 265–281, In
   Google Scholar
• Gross MM, Lewis E, Hastey J. Acute alcohol withdrawal syndrome. The biology of alcoholism. Vol. 3. Clinical pathology, B Kissin, H Begleiter. Plenum, New York 1974; 191–263, In
   Google Scholar
• Shaw JM, Kolesar GS, Sellers EM, Kaplan HL, Sandor P. Development of optimal treatment tactics for alcohol withdrawal. 1. Assessment and effectiveness of supportive care. J Clin Psychopharmacol 1981; 1: 382–389
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Sellers EM, Chater K, Iversen P, Roach C, Sykora K. Non-pharmacologic intervention in acute alcohol withdrawal. Clin Pharmacol 1983; 34: 214–219
   Google Scholar
• Sellers EM, Naranjo CA, Harrison M, Devenyi P, Roach C, Sykora K. Diazepam loading: Simplified treatment of alcohol withdrawal. Clin Pharmacol Ther 1983; 34: 822–826
   PubMed Web of Science ®Google Scholar
• Moskowitz G, Chalmers TC, Sacks HS, Fagerstrom RM, Smith H. Deficiencies of Clinical Trials of Alcohol Withdrawal. Alcoholism (NY) 1983; 7: 42–46
   Web of Science ®Google Scholar
• Busto U, Simpkins J, Sellers EM, Sisson B, Segal R. Objective determination of benzodiazepine use and abuse in alcoholics. Br J Addict 1983; 78: 429–435
   PubMedGoogle Scholar
• Carlen PL, Wu PH. Calcium and sedative-hypnotic drug actions. International review of neurobiology. Academic Press, New York 1987; 29, In
   Google Scholar
• Little HJ, Dolin SJ, Halsey MJ. Calcium channel antagonists decrease the ethanol withdrawal syndrome. Life Sci 1986; 34: 2059–2065
   Google Scholar
• Hudspith MJ, Brennan CH, Charles S, Littleton JM. Dihydropyridine-sensitive Ca2+ channels and inositol phospholipid metabolism in ethanol dependence. Ann NY Acad Sci 1987; 492: 156–169
   PubMed Web of Science ®Google Scholar
• Wu PH, Fan T, Naranjo CA. Brain voltage-sensitive calcium channels are associated with ethanol tolerance and withdrawal. J Neurochem 1987; 48: S109–S109, (Suppl.)
   Google Scholar
• Wu PH, Fan T, Naranjo CA. Increase in the brain regional depolarization-dependent Ca2 + uptake in rats preferring ethanol. Pharmacol Biochem Behav 1987; 27: 355–357
   PubMed Web of Science ®Google Scholar
• Wu PH, Fan T, Naranjo CA. Nifedipine delays the acquisition of tolerance to ethanol. Eur J Pharmacol 1987, (in press)
   Web of Science ®Google Scholar
• Naranjo CA, Sellers EM, Lawrin MO. Modulation of ethanol intake by serotonin uptake inhibitors. J Clin Psychiatry 1986; 47: 16–22
   PubMed Web of Science ®Google Scholar
• Peachey JE, Naranjo CA. The use of disulfiram and other alcohol-sensitizing drugs in the treatment of alcoholism. Research advances in alcohol and drug problems, Y Israel, FB Glaser, H Kalant, RE Popham, W Schmidt, RE Smart. Plenum, New York 1983; 7: 397–431, In
   Google Scholar
• Fuller, RK, Branchey, L, Brightwell, DR, Derman, RM, Emrick, CD, Iber, FL, et al. Disulfiram treatment of alcoholism. A Veterans Administration Cooperative Study. JAMA 1986; 257: 1449–1455
   Google Scholar
• Lawrin MO, Naranjo CA, Sellers EM. Identification and testing of new drugs for modulating alcohol consumption. Psychopharmacol Bull 1986; 22: 1020–1025
   Web of Science ®Google Scholar
• Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K. Zimelidine-induced variations in alcohol intake by non-depressed heavy drinkers. Clin Pharmacol Ther 1984; 35: 374–381
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, Sykora K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 1987; 41: 266–274
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Sellers EM, Sullivan JT, Kadlec KE, Woodley DV, Kennedy G. Viqualine-induced attenuation of ethanol intake in early stage problem drinkers. Proceedings of the tenth International Congress on Pharmacology, Sydney, 1987, (in press)
   Google Scholar
• Naranjo CA, Sellers EM. Serotonin uptake inhibitors attenuate ethanol intake in humans. Aust Alcohol Drug Rev 1988; 7, (in press)
   Google Scholar
• Martin PR, Adinoff B, Weingartner H, Mukherjee AB, Eckardt MJ. Alcoholic organic brain disease. Nosology and pathophysiologic mechanisms. Prog Neuro-Psychopharmacol Biol Psychiatry 1986; 10: 147–164
   PubMed Web of Science ®Google Scholar
• Martin PR, Adinoff B, Bone GAH, Stapleton JM, Eckardt MJ, Linnoila M. Fluvoxamine (F) treatment of alcoholic chronic organic brain syndromes (COBS). Clin Pharmacol Ther 1987; 41: 211–211, (Abst)
   Web of Science ®Google Scholar
• Israel Y, Orrego H. Hypermetabolic state and hypoxic liver damage. Recent developments in alcoholism, M Galanter. Plenum, New York 1984; 2: 119–133, In
   Google Scholar
• Orrego, H, Kalant, H, Israel, Y, Blake, J, Medline, A, Rankin, JG, et al. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver diseases. Gastroenterology 1979; 767: 105–115
   Google Scholar
• Orrego H, Blake JE, Blendis LM, Compton KV, Israel Y. Long-term propylthiouracil treatment reduced mortality in alcoholic liver disease. N Engl J Med 1987, (in press)
   PubMed Web of Science ®Google Scholar